Weekly Recap: Mexican patent extension to 2040 and ATM share sale
Moleculin Biotech, Inc. (NASDAQ:MBRX) strengthened its IP with a Mexican patent on liposomal Annamycin to Nov 23, 2040 supporting the MIRACLE AML trial, reported preclinical pancreatic tumor and CD8+ T—cell data and raised about $0.48M via a Sept ATM sale of 888,400 shares.Previous Week RecapThis i…